<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39438611</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>One-year mortality and associated factors in older hospitalized COVID-19 survivors: a Nationwide Cohort Study in Korea.</ArticleTitle><Pagination><StartPage>24889</StartPage><MedlinePgn>24889</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24889</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-76871-3</ELocationID><Abstract><AbstractText>This study aimed to evaluate the 1-year mortality rate among older patients with COVID-19 discharged from hospital and to identify risk factors associated with this outcome. Using a COVID-19 dataset from the Korean National Health Insurance System, this study's evaluation period spanned from October 8, 2020, through December 31, 2021. The primary outcome was the 1-year mortality rate following hospital discharge. A logistic regression model was employed for multivariable analysis to estimate the odds ratios for the outcomes, and the Kaplan-Meier method was used to analyze differences in 1-year survival rates. Among the 66,810 COVID-19 patients aged 60 years or older who were hospitalized during the study period, the in-hospital mortality rate was 4.8% (n = 3219). Among the survivors (n = 63,369), the 1-year mortality rate was 4.9% (n = 3093). Non-survivors, compared to survivors, were significantly older (79.2 ± 9.5 vs. 68.9 ± 7.8, P &lt; 0.001) and exhibited a lower rate of COVID-19 vaccination (63.0% vs. 91.7%, P &lt; 0.001). Additionally, non-survivors experienced a higher incidence of organ dysfunction, along with a greater proportion of required mechanical ventilation (14.6% vs. 1.0%, P &lt; 0.001) and extracorporeal membrane oxygenation (4.0% vs. 0.1%, P &lt; 0.001). Multivariable logistic regression analysis identified older age, male sex, cardiovascular disease, immunosuppression, organ dysfunction, illness severity, and corticosteroid use during hospitalization as factors associated with death within 1 year after hospital discharge. However, vaccination was found to have a long-term protective effect against death among COVID-19 survivors. The 1-year mortality rate after hospital discharge for older COVID-19 patients was comparable to the in-hospital mortality rate for these patients in Korea. The long-term mortality rate among hospitalized older COVID-19 patients was influenced by demographic factors and the severity of illness experienced during hospitalization.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Eunji</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Global Innovative Drugs, The Graduate School of Chung‑Ang University, Chung‑Ang University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jeong-Yeon</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Global Innovative Drugs, The Graduate School of Chung‑Ang University, Chung‑Ang University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>Kyoung Min</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-ro, Dongjak-gu, Seoul, 06973, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae Wan</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-ro, Dongjak-gu, Seoul, 06973, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Won-Young</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-ro, Dongjak-gu, Seoul, 06973, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Jung</LastName><ForeName>Sun-Young</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Global Innovative Drugs, The Graduate School of Chung‑Ang University, Chung‑Ang University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Pharmacy, Chung‑Ang University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Baek</LastName><ForeName>Moon Seong</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-ro, Dongjak-gu, Seoul, 06973, Republic of Korea. wido21@cau.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research Institute, Chung-Ang University Hospital, Seoul, Republic of Korea. wido21@cau.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2023</GrantID><Agency>Biomedical Research Institute of Chung-Ang University Hospital</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="Y">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="Y">Survivors</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age factors</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Critical illness</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Survivors</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>23</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39438611</ArticleId><ArticleId IdType="pmc">PMC11496793</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-76871-3</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-76871-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thygesen, J. H. et al. COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records. Lancet Digit. Health. 4, e542–e557. 10.1016/s2589-7500(22)00091-7 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9179175</ArticleId><ArticleId IdType="pubmed">35690576</ArticleId></ArticleIdList></Reference><Reference><Citation>Baptista, A., Vieira, A. M., Capela, E., Julião, P. &amp; Macedo, A. COVID-19 fatality rates in hospitalized patients: a new systematic review and meta-analysis. J. Infect. Public. Health. 16, 1606–1612. 10.1016/j.jiph.2023.07.006 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37579698</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, L. et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir. Med.10, 863–876. 10.1016/s2213-2600(22)00126-6 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, H. E., McCorkell, L., Vogel, J. M., Topol, E. J. &amp; Long, C. O. V. I. D. Major findings, mechanisms and recommendations. Nat. Rev. Microbiol.21, 133–146. 10.1038/s41579-022-00846-2 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwashyna, T. J. et al. Late mortality after COVID-19 infection among US veterans vs risk-matched comparators: a 2-year cohort analysis. JAMA Intern. Med.10.1001/jamainternmed.2023.3587 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10442778</ArticleId><ArticleId IdType="pubmed">37603339</ArticleId></ArticleIdList></Reference><Reference><Citation>Hägglöf, E., Bell, M., Zettersten, E., Engerström, L. &amp; Larsson, E. Long-term survival after intensive care for COVID-19: a nationwide cohort study of more than 8000 patients. Ann. Intensive Care13, 76. 10.1186/s13613-023-01156-3 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10465451</ArticleId><ArticleId IdType="pubmed">37642833</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillon, A., Laurent, E., Godillon, L., Kimmoun, A. &amp; Grammatico-Guillon, L. Long-term mortality of elderly patients after intensive care unit admission for COVID-19. Intensive Care Med.47, 710–712. 10.1007/s00134-021-06399-x (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8040757</ArticleId><ArticleId IdType="pubmed">33844045</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodd, L. E. et al. Endpoints for randomized controlled clinical trials for COVID-19 treatments. Clin. Trials17, 472–482. 10.1177/1740774520939938 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611901</ArticleId><ArticleId IdType="pubmed">32674594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramzi, Z. S. Hospital readmissions and post-discharge all-cause mortality in COVID-19 recovered patients; a systematic review and meta-analysis. Am. J. Emerg. Med.51, 267–279. 10.1016/j.ajem.2021.10.059 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8570797</ArticleId><ArticleId IdType="pubmed">34781153</ArticleId></ArticleIdList></Reference><Reference><Citation>Estimating excess mortality. Due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet399, 1513–1536. 10.1016/s0140-6736(21)02796-3 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8912932</ArticleId><ArticleId IdType="pubmed">35279232</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, C., Jang, H. &amp; Oh, J. Excess mortality during the coronavirus disease pandemic in Korea. BMC Public. Health23, 1698. 10.1186/s12889-023-16546-2 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10474701</ArticleId><ArticleId IdType="pubmed">37660007</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, T. H. et al. Survival benefit of a third dose of the COVID-19 vaccine among hemodialysis patients: a prospective cohort study. J. Microbiol. Immunol. Infect.56, 1198–1206. 10.1016/j.jmii.2023.09.002 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37770324</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi, B. et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. Bmj380, e072529. 10.1136/bmj-2022-072529 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos, M. M. S. et al. Predictors of early and long-term mortality after ICU discharge in critically ill COVID-19 patients: a prospective cohort study. PLoS One18, e0293883. 10.1371/journal.pone.0293883 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10621933</ArticleId><ArticleId IdType="pubmed">37917761</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourhoseingholi, M. A. et al. Predicting 1-year post-COVID-19 mortality based on chest computed tomography scan. J. Med. Virol.93, 5694–5696. 10.1002/jmv.27146 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8427075</ArticleId><ArticleId IdType="pubmed">34152618</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Bari, M. et al. COVID-19, vulnerability, and long-term mortality in hospitalized and nonhospitalized older persons. J. Am. Med. Dir. Assoc.23, 414–420e411. 10.1016/j.jamda.2021.12.009 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8673732</ArticleId><ArticleId IdType="pubmed">34990587</ArticleId></ArticleIdList></Reference><Reference><Citation>Uusküla, A. et al. Long-term mortality following SARS-CoV-2 infection: a national cohort study from Estonia. Lancet Reg. Health Eur.18, 100394. 10.1016/j.lanepe.2022.100394 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9051903</ArticleId><ArticleId IdType="pubmed">35505834</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby, P. et al. Dexamethasone in hospitalized patients with Covid-19. N Engl. J. Med.384, 693–704. 10.1056/NEJMoa2021436 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Munch, M. W. et al. Effect of 12 mg vs 6 mg of Dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 Randomized Trial. Jama326, 1807–1817. 10.1001/jama.2021.18295 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8532039</ArticleId><ArticleId IdType="pubmed">34673895</ArticleId></ArticleIdList></Reference><Reference><Citation>Günster, C. et al. 6-month mortality and readmissions of hospitalized COVID-19 patients: a nationwide cohort study of 8,679 patients in Germany. PLoS One16, e0255427. 10.1371/journal.pone.0255427 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8341502</ArticleId><ArticleId IdType="pubmed">34351975</ArticleId></ArticleIdList></Reference><Reference><Citation>Merdji, H. et al. Sex and gender differences in intensive care medicine. Intensive Care Med.49, 1155–1167. 10.1007/s00134-023-07194-6 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10556182</ArticleId><ArticleId IdType="pubmed">37676504</ArticleId></ArticleIdList></Reference><Reference><Citation>Zettersten, E. et al. Long-term outcome after intensive care for COVID-19: differences between men and women-a nationwide cohort study. Crit. Care25, 86. 10.1186/s13054-021-03511-x (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7906087</ArticleId><ArticleId IdType="pubmed">33632273</ArticleId></ArticleIdList></Reference><Reference><Citation>Graña, C. et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst. Rev.12 Cd015477 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9726273</ArticleId><ArticleId IdType="pubmed">36473651</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian, V. et al. Risk factors Associated with Post-COVID-19 Condition: a systematic review and Meta-analysis. JAMA Intern. Med.183, 566–580. 10.1001/jamainternmed.2023.0750 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam, I. C. H. et al. Persistence in risk and effect of COVID-19 vaccination on long-term health consequences after SARS-CoV-2 infection. Nat. Commun.15, 1716. 10.1038/s41467-024-45953-1 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10894867</ArticleId><ArticleId IdType="pubmed">38403654</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernández-de-Las-Peñas, C. et al. Differences in Long-COVID symptoms between Vaccinated and non-vaccinated (BNT162b2 vaccine) hospitalized COVID-19 survivors infected with the delta variant. Vaccines (Basel)1010.3390/vaccines10091481 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9504977</ArticleId><ArticleId IdType="pubmed">36146560</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso, D., Piazza, M., Boner, A. L., Bellanti, J. A. &amp; Long, C. O. V. I. D. A proposed hypothesis-driven model of viral persistence for the pathophysiology of the syndrome. Allergy Asthma Proc.43, 187–193. 10.2500/aap.2022.43.220018 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9106095</ArticleId><ArticleId IdType="pubmed">35524358</ArticleId></ArticleIdList></Reference><Reference><Citation>Pazukhina, E. et al. Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID). BMC Med.20, 244. 10.1186/s12916-022-02448-4 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9257572</ArticleId><ArticleId IdType="pubmed">35794549</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit, D. et al. Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19. Clin. Exp. Allergy. 51, 1107–1120. 10.1111/cea.13997 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8444748</ArticleId><ArticleId IdType="pubmed">34351016</ArticleId></ArticleIdList></Reference><Reference><Citation>Patients Diagnosed with Post-COVID Conditions. An analysis of private healthcare claims using the oficial ICD-10 diagnostic code. http://resource.nlm.nih.gov/9918504887106676</Citation></Reference><Reference><Citation>Cho, H. W., Song, I. A. &amp; Oh, T. K. Quality of life and long-term mortality among survivors of extracorporeal membrane oxygenation: a Nationwide Cohort Study in South Korea. Crit. Care Med.49, e771–e780. 10.1097/ccm.0000000000005015 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34261933</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamdar, B. B. et al. Joblessness and lost earnings after acute respiratory distress syndrome in a 1-year national multicenter study. Am. J. Respir Crit. Care Med.196, 1012–1020. 10.1164/rccm.201611-2327OC (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5649982</ArticleId><ArticleId IdType="pubmed">28448162</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, B. W. et al. Death toll of COVID-19 on Asian americans: disparities revealed. J. Gen. Intern. Med.36, 3545–3549. 10.1007/s11606-021-07003-0 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8335981</ArticleId><ArticleId IdType="pubmed">34347256</ArticleId></ArticleIdList></Reference><Reference><Citation>Holbig, H. Navigating the dual dilemma between lives, rights and livelihoods: COVID-19 responses in China, Singapore, and South Korea. Z. für Vergleichende Politikwissenschaft16, 707–731. 10.1007/s12286-023-00555-x (2022).</Citation></Reference><Reference><Citation>Adjaye-Gbewonyo, D., Vahratian, A., Perrine, C. G. &amp; Bertolli, J. Long COVID in adults: United States, 2022. NCHS Data Brief., 1–8. (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37756137</ArticleId></ArticleIdList></Reference><Reference><Citation>Cañas, A. et al. Racial and ethnic disparities post-hospitalization for COVID-19: barriers to access to care for survivors of COVID-19 acute respiratory distress syndrome. Sci. Rep.14, 11556. 10.1038/s41598-024-61097-0 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11109289</ArticleId><ArticleId IdType="pubmed">38773184</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowles, K. H. et al. Surviving COVID-19 after Hospital discharge: symptom, functional, and adverse outcomes of home health recipients. Ann. Intern. Med.174, 316–325. 10.7326/m20-5206 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7707212</ArticleId><ArticleId IdType="pubmed">33226861</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyberg, T. et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. Bmj373, n1412. 10.1136/bmj.n1412 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8204098</ArticleId><ArticleId IdType="pubmed">34130987</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal, M. A., Ziaeian, B., Lavie, C. J. &amp; Fonarow, G. C. Cardiovascular disease in hospitalized patients with a diagnosis of coronavirus from the pre-COVID-19 era in United States: national analysis from 2016–2017. Mayo Clin. Proc.95, 2674–2683. 10.1016/j.mayocp.2020.09.022 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7508501</ArticleId><ArticleId IdType="pubmed">33276839</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek, M. S., Lee, M. T., Kim, W. Y., Choi, J. C. &amp; Jung, S. Y. COVID-19-related outcomes in immunocompromised patients: a nationwide study in Korea. PLoS One16, e0257641. 10.1371/journal.pone.0257641 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8486114</ArticleId><ArticleId IdType="pubmed">34597325</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, H. R., Song, I. A. &amp; Oh, T. K. Quality of life and mortality among survivors of acute respiratory distress syndrome in South Korea: a nationwide cohort study. J. Anesth.36, 230–238. 10.1007/s00540-022-03036-9 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8777182</ArticleId><ArticleId IdType="pubmed">35061069</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>